PRTA
NASDAQProthena Corporation plc
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$10.74-0.03 (-0.28%)
01:45 PM07:45 PM
News · 26 weeks34-75%
2025-10-262026-04-19
Mix2390d
- Insider9(39%)
- SEC Filings6(26%)
- Other6(26%)
- Earnings2(9%)
Latest news
25 items- INSIDERSEC Form 4 filed by Kingston Anne Evans4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
- INSIDERSEC Form 3 filed by new insider Kingston Anne Evans3 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
- PRProthena Announces Leadership Team UpdatesProthena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced updates to its leadership team. Annie Kingston is being promoted to Chief Strategy Officer and Michael Isaacs is being promoted to General Counsel and Corporate Secretary. Mr. Isaacs succeeds Michael Malecek who will be departing from Prothena. Ms. Kingston and Mr. Isaacs will join Prothena's leadership team and will report to Gene Kinney, Ph.D., President and Chief Executive Officer. Ms. Kingston's promotion is effective immediately and Mr. Isaacs' promotion will take effect following Mr. Malecek
- SECSEC Form DEFA14A filed by Prothena Corporation plcDEFA14A - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer)
- SECSEC Form DEF 14A filed by Prothena Corporation plcDEF 14A - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer)
- PRProthena Partners Present Data Supporting Next Generation Treatments for Parkinson's and Alzheimer's Disease at AD/PD™ 2026Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced partner presentations on clinical updates from prasinezumab for the treatment of Parkinson's disease and BMS-986446 for the treatment of Alzheimer's disease at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD™ 2026) in Copenhagen, Denmark, and online. Roche Presentations on Prasinezumab for the Potential Treatment of Parkinson's Disease Industry Symposium – Pathways to Progress: Exploring Innovations in AD and PD for Future Practice
- PRProthena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with CardiomyopathyCoramitug is a potential first-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy1-3 Prothena has now earned $150 million to date of the $1.2 billion total eligible milestone payments from Novo Nordisk Prothena Corporation plc (NASDAQ:PRTA) today announced that the Company earned a $50 million milestone payment from Novo Nordisk related to the achievement of a prespecified enrollment target in the ongoing Phase 3 CLEOPATTRA clinical trial evaluating coramitug (formerly PRX004), a potential first-in-class amyloid depleter antibody, for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). Novo Nordisk is evaluating coramitug in th
- INSIDERSEC Form 4 filed by Chief Scientific Officer Zago Wagner M.4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
- INSIDERSEC Form 4 filed by Chief Accounting Officer Walker Karin L4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
- INSIDERSEC Form 4 filed by Chief Development Officer Swanson Chad J.4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
- INSIDERSEC Form 4 filed by Chief Operating Officer Smith Brandon S.4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
- INSIDERSEC Form 4 filed by Chief Strategy Officer and CFO Nguyen Tran4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
- INSIDERSEC Form 4 filed by Chief Legal Officer Malecek Michael J4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
- INSIDERSEC Form 4 filed by President and CEO Kinney Gene G.4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
- SECSEC Form EFFECT filed by Prothena Corporation plcEFFECT - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer)
- SECProthena Corporation plc filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer)
- SECSEC Form POS AM filed by Prothena Corporation plcPOS AM - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer)
- PRProthena Announces up to $100 Million Share Repurchase PlanProthena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that its Board of Directors has authorized a Share Repurchase Plan under which the Company may repurchase up to $100.0 million of the Company's outstanding ordinary shares, par value $0.01 per share. Prothena had cash, cash equivalents and restricted cash of $308.4 million and no debt as of December 31, 2025. Excluding any potential purchases under this Share Repurchase Plan, Prothena expects to end the year with approximately $255 million in cash, cash equivalents, and restricted cash. This fin
- SECSEC Form 10-K filed by Prothena Corporation plc10-K - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer)
- SECSEC Form POSASR filed by Prothena Corporation plcPOSASR - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer)
- SECProthena Corporation plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer)
- PRProthena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business HighlightsNet cash used in operating and investing activities was $23.3 million and $163.7 million for the fourth quarter and full year of 2025, respectively; quarter-end cash and restricted cash position was $308.4 million Prothena expects the full year 2026 net cash used in operating and investing activities to be $50 to $55 million and expects to end the year with approximately $255 million in cash (midpoint). Financial guidance does not include the potential to earn up to $105 million in aggregate clinical milestone payments from strategic partners in 2026 Roche initiated the Phase 3 PARAISO trial evaluating prasinezumab in early-stage Parkinson's disease in 4Q 2025; primary completion exp
- PRProthena to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its fourth quarter and full year 2025 financial results on Thursday, February 19, 2026, after the close of the U.S. financial markets. The announcement will be followed by a live audio conference call at 4:30 PM ET. The conference call will be made available on the Company's website at www.prothena.com under the Investors tab in the Events and Presentations section. Following the live audio webcast, a replay will be available on the Company's website for at least 90 days. T
- SECProthena Corporation plc filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer)
- PRProthena Announces Board of Directors UpdateProthena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that Paula Cobb will step down from Prothena's Board of Directors to join Manifold Bio as its Chief Operating Officer. During her six-year tenure, Ms. Cobb played a significant role in which she made key contributions to the Company's vision and strategy. "I would like to thank Paula for her many contributions during the past six years. As a biotechnology executive with wide-ranging global development, business strategy and commercial expertise, she provided valuable insights to the board and lea